PPTA Twitter

PlasmaProteins " #PlasmaProtein therapies provide immeasurable value by increasing survival rates, bolstering patient health, and enabling individuals to participate as productive members of society."- @BatesWhiteEcon bit.ly/2Bqbitk
1 day ago.
PlasmaProteins Bleeding disorders, such as #hemophilia A & B, are caused by a missing clotting factor protein which helps control bleeding. About 30,000 individuals with bleeding disorders in the U.S. are treated with #plasmaprotein therapies. #ShowYourStripes bit.ly/2GBG7ZW pic.twitter.com/2F2KUG6QJH
4 days ago.

Plasma Protein Therapeutics Association

The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions.

Erica XLA

PPTA works globally to:

    • Advocate for access to and affordability of therapies for patients
    • Engage in constructive dialogue with regulatory agencies
    • Collaborate with patient advocacy organizations

PPTA also administers standards and programs that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100